A comparative trial of praziquantel, metrifonate and niridazole against Schistosoma haematobium.
Praziquantel administered in a single oral dose of 30 mg kg-1 to subjects infected with Schistosoma haematobium produced minimal side effects and was more effective than established regimes of niridazole and metrifonate. Praziquantel should prove a major tool in schistosomiasis control programmes.
D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D009560:Niridazole / Q000009:adverse effects / Q000627:therapeutic use*; D011223:Praziquantel / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D012548:Schistosoma haematobium / Q000187:drug effects; D012552:Schistosomiasis / Q000188:drug therapy*; D014236:Trichlorfon / Q000009:adverse effects / Q000627:therapeutic use*
D007546:Isoquinolines; D011223:Praziquantel; D014236:Trichlorfon; D009560:Niridazole